An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

NCT05526157 · clinicaltrials.gov ↗

COMPLETED

Status

50000

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease
Type 2 Diabetes Mellitus

Interventions

DRUG: Finerenone (Kerendia, BAY 948862)
DRUG: Sodium-glucose cotransporter 2 inhibitors (SGLT2i)
DRUG: Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
DRUG: Steroidal mineral corticoid receptor antagonists (sMRA)
DRUG: Non-steroidal mineral corticoid receptor antagonists (nsMRA)

Sponsor

Bayer